Request Demo
Last update 20 Mar 2026
SYH2053
Last update 20 Mar 2026
Overview
Basic Info
Drug Type siRNA |
Synonyms SYH2053 |
Target |
Action inhibitors |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our RNA technology data.
login
or
Related
6
Clinical Trials associated with SYH2053NCT07421297
A Phase Ⅲ Randomized, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety of the SYH2053 Subcutaneous Injection as Monotherapy in Participants With Primary Hypercholesterolemia (Non-familial) or Mixed Dyslipidemia
NCT07465263
A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Trial
CTR20251534
一项在中国低密度脂蛋白胆固醇正常或升高参与者中评价SYH2053注射液对阿托伐他汀钙片药代动力学影响的I期临床试验
[Translation] A phase I clinical trial evaluating the effect of SYH2053 injection on the pharmacokinetics of atorvastatin calcium tablets in Chinese participants with normal or elevated low-density lipoprotein cholesterol
100 Clinical Results associated with SYH2053
Login to view more data
100 Translational Medicine associated with SYH2053
Login to view more data
100 Patents (Medical) associated with SYH2053
Login to view more data
100 Deals associated with SYH2053
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Mixed hyperlipidemia | Phase 3 | China | 01 Apr 2026 | |
| Heterozygous familial hypercholesterolemia | Phase 3 | China | 09 Mar 2026 | |
| Heterozygous familial hypercholesterolemia | Phase 3 | China | 09 Mar 2026 | |
| Complex dyslipidemia | Phase 3 | China | 25 Feb 2026 | |
| Complex dyslipidemia | Phase 3 | China | 25 Feb 2026 | |
| Primary hypercholesterolemia | Phase 3 | China | 25 Feb 2026 | |
| Primary hypercholesterolemia | Phase 3 | China | 25 Feb 2026 | |
| Combined hyperlipidemia | Phase 2 | China | 03 Dec 2024 | |
| Combined hyperlipidemia | Phase 2 | China | 03 Dec 2024 | |
| Hyperlipidemia, Familial Combined | Phase 1 | China | 08 Jan 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free